Home >> WEBINARS >> Practical considerations and real-world examples: CAP/IASLC/AMP molecular testing guideline updates for NSCLC

Practical considerations and real-world examples: CAP/IASLC/AMP molecular testing guideline updates for NSCLC

Print Friendly, PDF & Email

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Webinar presenter Michelle Shiller, DO, MSPT, discusses key updates to the CAP/IASLC/AMP guideline recommendations for molecular testing in patients with NSCLC and the impact of the CAP/IASLC/AMP guideline recommendations on clinical practice illustrated through testing case scenarios. This on-demand webinar originally broadcast on May 9, 2018.

CAP TODAY does not endorse any of the products or services named within. US-19418 Last Updated 4/18

x

Check Also

Molecular lung cancer testing: from guideline to practice

August 2018—Testing turnaround times can affect whether non-small cell lung cancer patients receive an EGFR or ALK tyrosine kinase inhibitor when indicated. At disease progression on an EGFR TKI, integrating circulating tumor DNA and tissue-based testing may lessen some of the limitations of each form of testing.

X